Tuesday, September 02, 2008

New England Journal of Medicine: Vytorin/Zetia cancer increase should not be assumed to be a chance finding until further data are in.

"The fact that the combined data from all three trials showed an increase in cancer mortality with ezetimibe [Zetia] should not be assumed to be a chance finding until further data are in. "

This bomb is delivered on NEJM's editorial page.

No comments: